GenScript Biotech

Last updated
GenScript Biotech Corporation
Company type Public
SEHK:  1548
Industry Life sciences
Founded2002 in New Jersey [1]
FoundersFangliang Zhang, Ye Wang, Luquan Wang
Headquarters Piscataway, NJ [2]
Area served
Worldwide
Key people
Shao Weihui, CEO
Website www.genscript.com OOjs UI icon edit-ltr-progressive.svg

GenScript Biotech, fully known as GenScript Biotech Corporation, usually referred to as simply GenScript, is a New Jersey-based biotech company. [3] [4] [5] It was co-founded in 2002 in New Jersey by Fangliang Zhang, Ye Wang, and Luquan Wang. [6] The company mainly provides life science research application instruments and services. [7] It was listed on the Hong Kong Stock Exchange in 2015. [8] The current rotating CEO of the firm is Shao Weihui, who also served as the chief operating officer and Chinese Communist Party Committee Secretary for the company. [9] [10] The company's main subsidiaries include Legend Biotech, [11] ProBio Technology, [12] and Bestzyme. [13]

Contents

Outside of the United States, GenScript has established presences in China, Singapore, Japan, the United Kingdom, and the Netherlands, among others. [14] The company's operations are divided into four main segments, CDMO platform, life-science services and products platform, integrated cell therapy platform, and industrial synthetic products platform. [14] In September 2021, the firm and its subsidiary Probio received series A funding from Hillhouse Capital. [15]

History

GenScript was formed in 2002 in New Jersey. In 2004, it set up a research and production base in Nanjing, China. [16] In 2009, the company secured a $15 million investment from KPCB China Fund. [17]

In 2011, the company opened a subsidiary in Japan. In 2013, it established Bestzyme. [16] In the following year, another subsidiary of the firm, Legend Biotech, was founded. [18] In 2015, GenScript went public on the SEHK.

In 2017, the Chinese government accepted Nanjing Legend's application for running clinical trials for its blood cancer treatment, [19] with its IND application approved by the CFDA. [20] In the same year, Legend Biotech USA Inc. and Legend Biotech Ireland Limited, non-wholly owned subsidiaries of GenScript, [21] entered into a collaboration agreement with Janssen Biotech [22] to share CAR-T treatments in the US and China. [23] Subsequently, GenScript fully acquired CustomArray. [24]

In 2020, its subsidiary Probio was launched. [25] In the same year, Genscript collaborated with Duke-NUS Medical School to develop and manufacture a serology test called cPass for the detection of COVID-19. [26] On November 6, the cPass test received emergency use authorization from the US FDA. [27] [28] Prior to that, Legend Biotech was listed on the NASDAQ under the symbol "LEGN". [29]

In 2022, Carvykti, a CAR-T cell therapy developed by Janssen Biotech and Legend Biotech, [25] was approved by the US FDA for the treatment of multiple myeloma in adult patients. [30] In the same year, it opened a protein and gene manufacturing facility in Singapore. [31]

In November 2023, Legend Biotech and Novartis signed an out-license deal to develop and manufacture Legend's chimeric antigen receptor (CAR-T) therapies, that go after delta-like ligand protein 3 (DLL3) including large cell neuroendocrine carcinoma candidate LB2102. Novartis will pay the New-Jersey-based biotech $100 million upfront, and Legend Biotech will be eligible to receive up to $1.01 billion in clinical, regulatory, and commercial milestone payments and tiered royalties. [32]

In May 2024, the United States House Select Committee on Strategic Competition between the United States and the Chinese Communist Party asked the Federal Bureau of Investigation (FBI) and Director of National Intelligence for a briefing on whether the Chinese government has any undue influence over GenScript and three of its subsidiaries (Bestzyme, Legend Biotech, and ProBio). [33] [34] GenScript's stock fell on the news. [35]

Related Research Articles

<span class="mw-page-title-main">Novartis</span> Swiss multinational pharmaceutical corporation

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.

Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. Historically, the company is regarded as the world's first biotechnology company.

<span class="mw-page-title-main">Amgen</span> American multinational biopharmaceutical company

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, As of 2022, Amgen has approximately 24,000 staff in total.

<span class="mw-page-title-main">Celgene</span> American biopharmaceutical company

Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).

<span class="mw-page-title-main">Regeneron Pharmaceuticals</span> American biotechnology company

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.

<span class="mw-page-title-main">Daiichi Sankyo</span> Japanese pharmaceutical company

Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. The company owns the American pharmaceutical company American Regent.

<span class="mw-page-title-main">Ofatumumab</span> Medication

Ofatumumab is a fully human monoclonal antibody to CD20, which appears to provide rapid B-cell depletion. Under the brand name Kesimpta, it is approved for the treatment of multiple sclerosis in the United States as well as in the European Union and other regions. Under the brand name Arzerra, it is approved for the treatment of certain types of chronic lymphocytic leukemia (CLL) in the United States. It is sold by Novartis under license from Genmab.

<span class="mw-page-title-main">Chugai Pharmaceutical Co.</span> Japanese pharmaceutical company

Chugai Pharmaceutical Co., Ltd. is a drug manufacturer operating in Japan. It is a subsidiary controlled by Hoffmann-La Roche, which owns 62% of the company as of 30 June 2014. The company is headquartered in Tokyo. Osamu Nagayama is the current representative director and chairman. Tatsuro Kosaka is the current representative director, president and CEO.

MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany, and has a wholly owned subsidiary, MorphoSys US Inc., in Boston, Massachusetts, in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.

<span class="mw-page-title-main">Merck & Co.</span> American multinational pharmaceutical company

Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of which it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. It is one of the largest pharmaceutical companies in the world, generally ranking in the global top five by revenue.

<span class="mw-page-title-main">Secukinumab</span> Monoclonal antibody against IL-17

Secukinumab, sold under the brand name Cosentyx among others, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It binds to the protein interleukin (IL)-17A and is marketed by Novartis.

<span class="mw-page-title-main">Daratumumab</span> Monoclonal antibody

Daratumumab, sold under the brand name Darzalex among others, is an anti-cancer monoclonal antibody medication. It binds to CD38, which is overexpressed in multiple myeloma cells. Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab.

<span class="mw-page-title-main">Nivolumab</span> Anticancer medication

Nivolumab, sold under the brand name Opdivo, is an anti-cancer medication used to treat a number of types of cancer. This includes melanoma, lung cancer, malignant pleural mesothelioma, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colon cancer, esophageal squamous cell carcinoma, liver cancer, gastric cancer, and esophageal or gastroesophageal junction cancer. It is administered intravenously.

<span class="mw-page-title-main">Moderna</span> American biotechnology company

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

<span class="mw-page-title-main">Ceritinib</span> ALK inhibitor for treatment of non-small-cell lung cancer

Ceritinib is a prescription-only drug used for the treatment of non-small cell lung cancer (NSCLC). It was developed by Novartis and received FDA approval for use in April 2014.

Dinutuximab and dinutuximab beta are monoclonal antibodies used as a second-line treatment for children with high-risk neuroblastoma. Each antibody is made of both mouse and human components and targets glycolipid GD2, expressed on neuroblastoma cells and on normal cells of neuroectodermal origin, including the central nervous system and peripheral nerves. They differ in that dinutuximab is manufactured using mouse cells, and dinutuximab beta is manufactured using hamster cells. The dosing regime differs, and dinutuximab is given in combination with granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), while dinutuximab beta can be given alone.

Tisagenlecleucel, sold under the brand name Kymriah, is a CAR T cells medication for the treatment of B-cell acute lymphoblastic leukemia (ALL) which uses the body's own T cells to fight cancer.

Inclisiran, sold under the brand name Leqvio, is a medication used for the treatment of high low-density lipoprotein (LDL) cholesterol and for the treatment of people with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk-equivalents, and heterozygous familial hypercholesterolemia (HeFH). It is a small interfering RNA (siRNA) that acts as an inhibitor of a proprotein convertase, specifically, inhibiting translation of the protein PCSK9.

AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology firm that researches and develops human antibodies. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.

BeiGene, Ltd. is a China-based drug developer. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the multinational company headquartered in Cambridge, Massachusetts has offices in North America, Europe, South America, Asia and Australia. BeiGene has a large presence in Chinese market. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor.

References

  1. ↑ Venus Feng and Yoojung Lee (May 31, 2018). "Road to Chinese Pharma Riches Runs Through the Bronx, New Jersey". Bloomberg News . Archived from the original on May 16, 2023.
  2. ↑ Dawn Furnas (May 26, 2022). "GenScript, fellow NJ biotech partner on COVID-19 antibody test distribution". NJBIZ. Archived from the original on May 16, 2023.
  3. ↑ Rick Mitchell (January 23, 2023). "Paul Hastings Advises GenScript, Probio on $224 Million Funding". Bloomberg Law . Archived from the original on May 16, 2023.
  4. ↑ Tim Gray (July 13, 2018). "The New Revolution Brought About by Gene Synthesis". The New York Times . Archived from the original on May 16, 2023.
  5. ↑ Kate Knibbs. "The Promise of Antibody Treatments for Covid-19". Wired . May 22, 2020. Archived from the original on May 16, 2023. Wired.com .
  6. ↑ Weijing Zhou. "KPCB invests $15 mln in Jinsite". 21st Century Business Herald. June 20, 2009. Archived from the original on May 17, 2023.
  7. ↑ Yuexiang Zhou (May 10, 2023). "Singapore Strives to Become Asia's Biomedical Hub". Lianhe Zaobao . Archived from the original on May 17, 2023.
  8. ↑ Eric Ng (December 22, 2017). "Genscript's shares jump by a third on US$350m Johnson & Johnson unit tie-up". South China Morning Post . Archived from the original on May 16, 2023.
  9. ↑ "Genscript Biotech Corporation Announces Chief Executive Officer Changes". MarketScreener. December 18, 2022. Archived from the original on June 20, 2023.
  10. ↑ "我院党委与金斯瑞集团党委举行党建共建暨校企合作签约仪式" [The Party Committee of our college and the Party Committee of GenScript Group held a signing ceremony for joint party building and school-enterprise cooperation]. Nanjing University (in Chinese). 2022-06-30. Archived from the original on June 30, 2022. Retrieved 2024-06-02.
  11. ↑ Russell Flannery (Forbes Staff) (June 7, 2020). "Johnson & Johnson Partner's Stock Soars As Investors Embrace China Health, Tech". Forbes . Archived from the original on June 18, 2023.
  12. ↑ Rick Mitchell (April 24, 2023). "Wake Up Call: Kirkland, Cole Schotz Advising Bed Bath & Beyond". Bloomberg Law . Archived from the original on June 17, 2023.
  13. ↑ Stephanie Li (May 31, 2023). "China Digest: Lynk Pharma, Bestzyme Bioengineering securing funding". DealStreetAsia . Archived from the original on June 18, 2023.
  14. 1 2 "GenScript Launches A Protein Manufacturing Facility In Singapore". Lianhe Zaobao . Economic Development Board. January 10, 2023. Archived from the original on June 17, 2023.
  15. ↑ "GenScript and Probio Close Series A Financing with Investment from Hillhouse". Paul Hastings . September 6, 2021. Archived from the original on June 10, 2023.
  16. 1 2 "Handbook of GenScript Biotech (2022 Edition)" (PDF). www.genscript.com. May 24, 2022. Archived (PDF) from the original on December 6, 2022.
  17. ↑ Jonathan Shieber (July 17, 2009). "Kleiner Perkins' Former Front Man In China Starts Fresh". The Wall Street Journal . Archived from the original on June 17, 2023.
  18. ↑ Preetika Rana (August 5, 2018). "How China Is Evolving From a Maker of Copycat Medicines Into a Producer of Complex Drugs". The Wall Street Journal . Archived from the original on May 16, 2023.
  19. ↑ Wei, Jianshu; Guo, Yelei; Wang, Yao; Wu, Zhiqiang; Bo, Jian; Zhang, Bin; Zhu, Jun; Han, Weidong (April 2021). "Clinical development of CAR T cell therapy in China: 2020 update". Cellular & Molecular Immunology. 18 (4): 792–804. doi:10.1038/s41423-020-00555-x. PMC   8115146 . PMID   32999455.
  20. ↑ Wei, Jianshu; Guo, Yelei; Wang, Yao; Wu, Zhiqiang; Bo, Jian; Zhang, Bin; Zhu, Jun; Han, Weidong (April 2021). "Clinical development of CAR T cell therapy in China: 2020 update". Cellular & Molecular Immunology. 18 (4): 792–804. doi:10.1038/s41423-020-00555-x. PMC   8115146 . PMID   32999455.
  21. ↑ "GenScript Biotech Releases Announcement of its Latest Research and Development". MarketScreener. August 5, 2020. Archived from the original on August 29, 2023. Retrieved June 1, 2024.
  22. ↑ Arpita Dutt (December 22, 2017). "Pharma Stock Roundup: Aerie's Rhopressa Approved, Label Expansion for BMY, Pfizer Drugs". Yahoo! Finance . Archived from the original on August 29, 2023.
  23. ↑ Will Ballard (October 10, 2019). "Chinese biotech: from copycat to innovator". Financial Times . ISSN   0307-1766. Archived from the original on August 29, 2023.
  24. ↑ Vince Iral (December 27, 2017). "Genscript Biotech to acquire US genomic sequencing company". S&P Global . Archived from the original on May 17, 2023.
  25. 1 2 Dede Williams (January 25, 2023). "GenScript Raises $224 Million in Fresh Capital". CHEManager. Archived from the original on June 10, 2023.
  26. ↑ Lovelyn Tagalag (May 15, 2020). "GenScript to collaborate with Singapore agency on COVID-19 test". S&P Global . Archived from the original on May 16, 2023.
  27. ↑ "Coronavirus (COVID-19) Update: FDA Authorizes First Test that Detects Neutralizing Antibodies from Recent or Prior SARS-CoV-2 Infection". www.fda.gov. Food and Drug Administration. November 6, 2020. Archived from the original on November 6, 2020.
  28. ↑ Tan, Chee-Wah; Chia, Wan-Ni; Young, Barnaby E.; Zhu, Feng; Lim, Beng-Lee; Sia, Wan-Rong; Thein, Tun-Linn; Chen, Mark I.-C.; Leo, Yee-Sin; Lye, David C.; Wang, Lin-Fa (7 October 2021). "Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors". New England Journal of Medicine . 385 (15): 1401–1406. doi:10.1056/NEJMoa2108453. PMC   8422514 . PMID   34407341.
  29. ↑ Lucinda Shen (June 5, 2020). "ZoomInfo raises nearly $1 billion in its IPO". Fortune . Archived from the original on May 17, 2023.
  30. ↑ Peter Loftus (February 28, 2022). "FDA Approves Cell-Based Multiple Myeloma Therapy Discovered in China". The Wall Street Journal . Archived from the original on May 16, 2023.
  31. ↑ Timothy Goh (February 10, 2022). "GenScript's manufacturing facility boosts S'pore's role in fight against pandemic". The Straits Times . Archived from the original on June 18, 2023.
  32. ↑ Ojha, Shreeyashi (2023-11-15). "Legend & Novartis sign $100m agreement - BioProcess Insider". BioProcess International. Retrieved 2023-11-30.[ permanent dead link ]
  33. ↑ Freifeld, Karen (May 31, 2024). "US lawmakers ask FBI for briefing on GenScript Biotech's links to China". Reuters . Retrieved May 31, 2024.
  34. ↑ "Moolenaar, Krishnamoorthi Request FBI & DNI Briefing on Chinese Communist Party-Linked Biotech Firm". Select Committee on the CCP . 2024-05-31. Archived from the original on 2024-06-02. Retrieved 2024-06-02.
  35. ↑ Qin, Sherry (June 3, 2024). "GenScript Biotech Shares Drop After U.S. Lawmakers Scrutinize Chinese Ties" . The Wall Street Journal . Archived from the original on 2024-06-03. Retrieved 2024-06-04.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.